NYSE: TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Drug Manufacturers - Specialty & Generic
After hours: $37.19(+2.28%) · as of 7:59 PM ET
Market Cap
$42.35B
52w High
$38.37
52w Low
$18.21
P/E
60.82
Volume
7.39M
Outstanding Shares
1.16B
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 96.75% over the last year. Revenue grew 4.13% over the trailing twelve months. Operating margin moved from 5.38% to 11.45%. Free cash flow grew 51.46% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/FCF range (78th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at 11.45% — continued expansion would be needed to justify the premium. Revenue growth of 4.13% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets.
Valuation
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 5 shares became 7
Profitability & growth
Analyst consensus
22
Buy
20
Hold
4
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est $0.72 · Revenue est $4.24B
View